Sweden· SE-20180611000034
Respreeza 4000 mg Pulver och vätska till infusionsvätska, lösning
A medicinal product containing human alfa-1-proteinase inhibitor, registered in Sweden by CSL Behring GmbH.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Human Alfa-1-Proteinase Inhibitor
- Manufacturer
- CSL Behring GmbH
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20180611000034
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Human alfa-1-proteinase inhibitor in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandProlastinaGrifols Deutschland GmbH
- NorwayProlastinaGrifols Deutschland GmbH
- IrelandProlastin 4000 mg, powder and solvent for solution for infusionGrifols Deutschland GmbH
- PolandRespreezaCSL Behring GmbH
- FranceALFALASTIN 33,33 mg/mL, poudre et solvant pour solution injectableLFB-BIOMEDICAMENTS
- CzechiaPROLASTINAGrifols Deutschland GmbH, Frankfurt
- IcelandRespreezaCSL Behring GmbH*
- United StatesGLASSIATakeda Pharmaceuticals America, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 20 EEA countries. Names it is sold under:
- Austria · Prolastin
- Belgium · Pulmolast
- Cyprus · Prolastina
- Czechia · Prolastina
- Germany · Prolastin
- Denmark · Prolastina
- Spain · Prolasplan, Prolastina
- Finland · Prolastina
- France · Alfalastin, Prolastin
- Greece · Prolastin
- Croatia · Prolastina
- Ireland · Prolastin
- Iceland · Respreeza
- Italy · Plitalfa, Prolastin
- Liechtenstein · Respreeza
- Netherlands · Prolastin
- Norway · Prolastina, Respreeza
- Poland · Prolastin, Prolastin, 4000 Mg
- Portugal · Prolastin
- Slovakia · Prolastina
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ef3b35fb-6763-4eae-94a6-4b4e584ae44f GET /v1/drugs/ef3b35fb-6763-4eae-94a6-4b4e584ae44f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20180611000034",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20180611000034",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/respreeza"
}See everything about human alfa-1-proteinase inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.